Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaċċini - attiva tilqim kontra mard ikkawżat minn streptococcus pneumoniae serotipi 4, 6b, 9v, 14, 18 c, 19f u 23f (inklużi sepsis, meninġite, pnewmonja, bacteraemia u otiti medja akuta) fit-trabi u tfal minn xahrejn sa ħames snin ta ' età. l-użu ta 'prevenar għandu jkun stabbilit fuq il-bażi ta' rakkomandazzjonijiet uffiċjali filwaqt li jitqiesu l-impatt ta 'mard invażiv fi gruppi differenti ta' età, kif ukoll il-varjabilità tal-epidemjoloġija tas-serotip f'żoni ġeografiċi differenti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - infezzjonijiet pnewmokokkali - vaċċini - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. ara t-taqsimiet 4. 4 u 5. 1 għal informazzjoni dwar il-protezzjoni kontra serotipi pnewmokokkiċi speċifiċi. apexxnar should be used in accordance with official recommendations. .

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ratiopharm gmbh - desloratadine - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - anti-istaminiċi għall-użu sistemiku, - desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v - desloratadine - rhinitis, allergic, perennial; rhinitis, allergic, seasonal - anti-istaminiċi għall-użu sistemiku, - desloratadine teva huwa indikat għas-serħan mis-sintomi assoċjati ma': rinite allerġika;urtikarja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group ptc ehf - desloratadine - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - anti-istaminiċi għall-użu sistemiku, - trattament ta 'rinite allerġika u urtikarja.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

elan pharma international ltd. - natalizumab - marda ta 'crohn - immunostimulanti, - it-trattament ta attiva minn moderata sa gravi marda ta 'crohn għat-tnaqqis ta' sinjali u sintomi, u l-induzzjoni u l-manteniment ta ' rispons u remissjoni, fl-pazjenti li ma kellhomx rispons minkejja sħiħ u adegwat matul it-terapija b'kortikosterojde u l-immunosuppressant; jew li huma intolleranti għal, jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressanti - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dechra regulatory b.v. - mirtazapine - psychoanaleptics, antidepressants in combination with psycholeptics - qtates - għall-piż tal-ġisem jiksbu fil-qtates jesperjenzaw foqra fl-aptit u l-piż tal-telf li jirriżulta minn mard kroniku tal-kundizzjonijiet mediċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rinite allerġika staġjonali - preparazzjonijiet imnieħer - trattament sintomatiku ta 'rinite allerġika staġjonali meta jkun akkumpanjat minn konġestjoni nażali.